AccessibilityHelpAbout Us
Haleon Plc logo

Haleon Plc(LSE) HLN

Market Cap£30.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)+19%
5 YearN/A
1 Year-5%
1 Month-4%
£3.41
-0.50%
-0.02Today
Haleon Plc last closing stock price
MetricPriceDate
Last closeGBX 340.502026-09-15
Haleon Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.95%GBX 337.302026-09-08
1 month-4.25%GBX 355.602026-08-14
3 month+1.76%GBX 334.602026-06-17
Year to date-9.15%GBX 374.802025-12-31
1 year-4.54%GBX 356.702025-09-15
3 year+3.28%GBX 329.702023-09-15
Since inception+18.98%GBX 2.882022-07-18

Haleon Plc Financials at a Glance

Market Cap

£30.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£11.15B

Net Income (TTM)

£1.62B

EPS (TTM)

£0.18

P/E Ratio

18.79

Dividend

£0.07

Beta (Volatility)

-0.10 (Low)

Price

£3.41

Volume

23,713,207

Open

£3.42

Previous Close

£3.41

Daily Range

£3.37 - £3.43

52-Week Range

£3.18 - £4.16

Estimated Earnings Date

Mar 4, 2027

HLN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Haleon Plc

Haleon plc operates as a global entity focused on developing, manufacturing, and marketing an array of consumer health products. The company offers a comprehensive selection of items, including therapeutic oral care, pain relief solutions, respiratory health aids, and dietary supplements.

Products and Services
  • Therapeutic oral care products like Sensodyne and Polident
  • Pain relief solutions including Panadol and Voltaren
  • Vitamins and dietary supplements such as Centrum
Growth Outlook
  • Revenue of £2.8 billion in Q2 2026, consistent with previous quarters
  • Operating income margin of 20.9% indicates strong operational efficiency
  • Continued investment in R&D to drive product innovation and market expansion
Financial Highlights
  • Net income of £381 million in Q2 2026, reflecting solid profitability
  • Trailing twelve months (TTM) gross profit margin of 65.6% demonstrates strong pricing power
  • Dividend yield of 2.07% offers attractive returns to shareholders
Haleon plc, incorporated in 2021, has established itself as a leader in the consumer health sector. The company’s diverse product portfolio, featuring well-known brands, positions it favorably in a competitive market. The recent financial performance highlights a stable revenue stream and robust profit margins, indicating effective management and operational strength. The focus on research and development suggests a commitment to innovation, which is essential for sustaining growth in the evolving healthcare landscape. With a solid dividend yield, Haleon presents an appealing option for investors seeking exposure to the healthcare sector.
AI Generated • Sep 6, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Brian James McNamara, MBA

Website

www.haleon.com

Headquarters

Weybridge, SU KT13 0NY, GB

HLN Financials

Key Financial Metrics (TTM)

Gross Margin

65.57%

Operating Margin

21.35%

Net Income Margin

14.55%

Return on Equity

9.89%

Return on Capital

9.89%

Return on Assets

4.98%

Earnings Yield

5.32%

Dividend Yield

2.13%

Payout Ratio

39.00%

Stock Overview

Market Cap

£30.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.80B

Volume

23.71M

Avg. Volume

22.09M

Financials (TTM)

Gross Profit

£7.31B

Operating Income

£2.38B

EBITDA

£2.86B

Operating Cash Flow

£1.52B

Capital Expenditure

-£336.00M

Free Cash Flow

£1.19B

Cash & ST Invst.

£826.00M

Total Debt

£8.25B

Haleon Plc Performance Analysis

Haleon Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 10,858,000,00013.8%
20232023-12-31GBP 11,302,000,0004.1%
20242024-12-31GBP 11,233,000,000-0.6%
20252025-12-31GBP 11,030,000,000-1.8%
Haleon Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-301.3%
Q42025-12-31N/A
Q12026-03-310.9%
Q22026-06-30N/A
Haleon Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP 0.11-23.7%
20232023-12-31GBP 0.11-1.4%
20242024-12-31GBP 0.1638.9%
20252025-12-31GBP 0.1817.5%
Haleon Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.9%
Q42025-12-31N/A
Q12026-03-31-11.5%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

£2.80B

+2.2%

Gross Profit

£1.85B

+4.8%

Gross Margin

66.10%

N/A

Market Cap

£30.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£1.23M

N/A

Employees

24,535

N/A

Net Income

£381.00M

-5.5%

EBITDA

£724.00M

+3.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

£826.00M

+22.2%

Total Debt

£8.25B

-3.4%

Accounts Receivable

£2.29B

+6.8%

Inventory

£1.07B

-5.2%

Long Term Debt

£6.29B

-18.1%

Short Term Debt

£1.96B

+126.6%

Return on Assets

4.98%

N/A

Return on Invested Capital

9.04%

N/A

Free Cash Flow

£467.00M

+0.3%

Operating Cash Flow

£522.00M

+1.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SN.LSmith & Nephew plc
£10.38-1.05%
HIK.LHikma Pharmaceuticals PLC
£15.57+0.84%
HCM.LHUTCHMED (China) Limited
£2.01+1.01%
AGY.LAllergy Therapeutics plc
£0.05+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
VEEAVeea
$5.71+149.34%
BITOProShares Trust - ProShares Bitcoin ETF
$10.23-3.58%
NVDANvidia
$212.17+0.57%
NOKNokia
$9.84+1.97%

Questions About HLN

What is the current price of Haleon Plc?

Haleon Plc is trading at £3.41 per share.

What is the 52-week range for Haleon Plc?

Over the past 52 weeks, Haleon Plc has traded between £3.18 and £4.16.

How much debt does Haleon Plc have?

As of the most recent reporting period, Haleon Plc reported total debt of £8.61B.

How much cash does Haleon Plc have on hand?

Haleon Plc reported £1.32B in cash and cash equivalents in its most recent financial results.

What is Haleon Plc’s dividend yield?

Haleon Plc currently has a dividend yield of 2.13%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services